Menu
Giotrif® (afatinib) approved in Europe as new oral treatment option for patients with ...
- Approval provides a new oral treatment option for patients with the second largest sub-type of non-small cell lung cancer (NSCLC), representing approximately 20-30% of NSCLC cases
- Approval of Giotrif® is based on results of the LUX-Lung 8 study, which showed significantly improved overall survival and progression-free survival compared to Tarceva® (erlotinib) in patients with squamous cell carcinoma of the lung
- Afatinib is already approved in more than 60 countries for the treatment of patients with EGFR mutation-positive NSCLC*
(BUSINESS WIRE)-- Boehringer Ingelheim today announced that the http://me-newswire.net//news/17544/en...
Dans la même rubrique :
Mercredi 19 Novembre 2025 - 15:00 Algérie : la BAD salue les grands chantiers lancés |
Mercredi 5 Novembre 2025 - 18:21 Tchad : Star Oil Tchad et Airtel Money s'allient pour accélérer l'inclusion financière |
Mardi 28 Octobre 2025 - 19:45 Tchad : Atelier de Formation sur l'Utilisation des Images par le Volet des Standards des Ménages (EHCVM) |
